Merck Halts Second Neuphoria Alzheimer’s Trial, Stocks Slip
MRK•Merck has discontinued another Alzheimer’s clinical trial in collaboration with Neuphoria, marking a second program termination under the partnership this year. The decision triggered share price declines for both companies.
1. Trial Cancellation
Merck announced the discontinuation of its latest Neuphoria-partnered Alzheimer’s clinical trial, representing the second program termination under this alliance within six months. The halted study was evaluating a small-molecule candidate designed to slow cognitive decline in early-stage patients.
2. Market Reaction
Following the announcement, both Merck and Neuphoria stocks fell in afternoon trading, with investors expressing concern over recurring setbacks. Volume spiked as traders reassessed the companies’ near-term growth prospects amid pipeline uncertainty.
3. Pipeline Outlook
The repeated trial cancellations under the Neuphoria partnership raise questions about the alliance’s viability and Merck’s broader Alzheimer’s strategy. Analysts will now focus on remaining pipeline assets and alternative therapeutic approaches in the neurodegenerative portfolio.
